To include your compound in the COVID-19 Resource Center, submit it here.

After aducanumab failure, Eisai to test another anti-amyloid mAb

With the announcement that Eisai plans to start yet another Phase III trial of an anti-amyloid candidate, Alzheimer's disease researcher Rudolph Tanzi told BioCentury he wouldn't enroll any more AD patients in trials of therapies based on the amyloid hypothesis.

The latest trial start came just one

Read the full 465 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers